Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms

被引:73
作者
Cho, Clifford S. [1 ]
Labow, Daniel M. [2 ]
Tang, Laura [3 ]
Klimstra, David S. [3 ]
Loeffler, Agnes G. [4 ]
Leverson, Glen E. [1 ]
Fong, Yuman [5 ]
Jarnagin, William R. [2 ]
D'Angelica, Michael I. [2 ]
Weber, Sharon M. [1 ]
Blumgart, Leslie H. [2 ]
DeMatteo, Ronald R. [2 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Sect Surg Oncol, Clin Sci Ctr H4 724,Dept Surg, Madison, WI 53792 USA
[2] Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol, Madison, WI 53792 USA
[5] Mem Sloan Kettering Canc Ctr, Gastr & Mixed Tumor Serv, New York, NY 10021 USA
关键词
neuroendocrine; liver; surgery; pathology; grade; metastases;
D O I
10.1002/cncr.23523
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The behavior of neuroendocrine neoplasms is poorly defined, and predictors of outcome after surgical resection have yet to be identified. Consequently, guidelines for treatment remain unclear. Current pathologic classification systems do not permit meaningful discrimination of hepatic neuroendocrine neoplasms. METHODS. The authors reviewed prospectively maintained databases from 2 institutions of patients who underwent hepatic resection for neuroendocrine neoplasms between 1990 and 2006. Patient, tumor, and operative characteristics were analyzed to identify factors associated with overall survival, progression-free survival, and symptom control. Hepatic neoplasms were stratified by using a 3-tier pathologic classification system based on the number of mitotic figures and the presence of tumor necrosis that was recently validated for pancreatic neuroendocrine neoplasms. RESULTS. Seventy patients were identified from the databases. Low-grade, intermediate-grade, and high-grade neoplasms were identified in 53%, 37%, and 10% of patients, respectively. After a median follow-up of 51 months, the median overall survival for all patients was 91 months, and it was 108 months when 7 patients with high-grade neuroendocrine carcinomas were excluded. Progressive disease was eventually observed in 81% of patients, and the median progression-free survival was 17 months. The median time to the onset of symptoms was 39 months for patients who presented with hormonal symptoms and 80 months for all patients. Histologic grade was associated with poorer overall and progression-free survival. CONCLUSIONS. When performed in a context of aggressive multimodality therapy, long-term outcomes after partial hepatectomy for hepatic neuroendocrine neoplasms were favorable; however, disease progression was eventually observed in the majority of patients. Several oncologic variables were associated with significant differences in survival after resection. A novel pathologic classification system appears to enhance prognostic stratification of patients with hepatic neuroendocrine neoplasms.
引用
收藏
页码:126 / 134
页数:9
相关论文
共 22 条
[1]   Hepatic neuroendocrine metastases: Does intervention alter outcomes? [J].
Chamberlain, RS ;
Canes, D ;
Brown, KT ;
Saltz, L ;
Jarnagin, W ;
Fong, YM ;
Blumgart, LH .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 190 (04) :432-445
[2]   Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? [J].
Chen, H ;
Hardacre, JM ;
Uzar, A ;
Cameron, JL ;
Choti, MA .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (01) :88-92
[3]   Hepatic cytoreduction followed by a novel long-acting somatostatin analog: A paradigm for intractable neuroendocrine tumors metastatic to the liver [J].
Chung, MH ;
Pisegna, J ;
Spirt, M ;
Giuliano, AE ;
Ye, W ;
Ramming, KP ;
Bilchik, AJ .
SURGERY, 2001, 130 (06) :954-962
[4]  
CUNNINGHAM JD, 1994, ARCH SURG-CHICAGO, V129, P1050
[5]  
DiBartolomeo M, 1996, CANCER-AM CANCER SOC, V77, P402, DOI 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO
[6]  
2-4
[7]   Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors - Variables affecting response rates and survival [J].
Gupta, S ;
Johnson, MM ;
Murthy, R ;
Ahrar, K ;
Wallace, MJ ;
Madoff, DC ;
McRae, SE ;
Hicks, ME ;
Rao, S ;
Vauthey, JN ;
Ajani, JA ;
Yao, JC .
CANCER, 2005, 104 (08) :1590-1602
[8]   Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups [J].
Hochwald, SN ;
Zee, S ;
Conlon, KC ;
Colleoni, R ;
Louie, O ;
Brennan, MF ;
Klimstra, DS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2633-2642
[9]   The gastroenteropancreatic neuroendocrine cell system and its tumors [J].
Klöppel, G ;
Perren, A ;
Heitz, PU .
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 :13-27
[10]   Achieving R0 resection for locally advanced gastric cancer: Is it worth the risk of multiorgan resection? [J].
Martin, RCG ;
Jaques, DP ;
Brennan, MF ;
Karpeh, M .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 194 (05) :568-577